Abstracts Archive - Page 139 of 2607 - ACR Meeting Abstracts

Abstract Number: 0141 • ACR Convergence 2025
Cytokine profiles in antiphospholipid syndrome
Xiangjun Liu¹, Yuzhou Gan², Chun Li³, Jianping Guo⁴, lei zhu⁵ and yuan jia³, ¹Peking University, Beijing, Beijing, China, ²University of Michigan, Ann Arbor, MI, ³Peking University People's Hospital, Beijing, China (People's Republic), ⁴Peking University People's Hospital, Beijing, Beijing, China, ⁵Affiliated Nantong Rehabilitation Hospital of Nantong University, Nantong, China (People's Republic)
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with unknown etiology. Inflammatory-mediated tissue damage plays an important role in APS. This study aimed to investigate…
Abstract Number: 0142 • ACR Convergence 2025
Risk Factors for Antiphospholipid Syndrome-associated Nephropathy: A Retrospective Cohort Analysis
Xiaohan Wei¹, Zhixia Yang², Haoyu Pan², Yuying Fan², Jinyi Qian², Shuyi Yu² and Hui Shi³, ¹Shanghai JiaoTong University, Shanghai, China (People's Republic), ²Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ³Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: To identify independent clinical and laboratory risk factors associated with antiphospholipid syndrome-associated nephropathy (APSN) and highlight the clinical importance of early screening in high-risk…
Abstract Number: 0043 • ACR Convergence 2025
Single-cell and Spatial Transcriptomic Profiling of Muscle Reveals Inflammatory Mechanisms in Anti-glycyl tRNA Synthetase Syndrome
Takuya Harada¹, Hiroyuki Yamashita¹, Ami Isoda¹, Ken Kawaue¹, Mayuko Hayashi¹, Yutaro Misawa¹, Aruto Yamamoto¹, Miyu Wakatsuki¹, Yuya Akiyama¹, Setsuko Oyama¹, Kyoko Motomura¹, Hiroyuki Takahashi¹, Akiko Mitsuo², Yuichi Goto³, Eisei Noiri³ and Hiroshi Kaneko¹, ¹Division of Rheumatic Diseases, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan, ²Division of Clinical Laboratory Medicine, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan, ³National Center Biobank Network, Tokyo, Japan
Background/Purpose: We characterized the spatial distribution of immune cells and identified hub genes within activated molecular networks in key immune cell populations, based on the…
Abstract Number: 0132 • ACR Convergence 2025
Increased Expression of Gas6 and Its Tyrosine Kinase Receptor Tyro3 Are Associated with Antiphospholipid Syndrome
Fanshu Li, Ranran Yao, Fanlei Hu, Liling Xu and Chun Li, Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China (People's Republic)
Background/Purpose: Growth arrest specific protein 6 (Gas6) is a member of the vitamin K-dependent protein family. It participates in apoptosis, inflammatory response and immunomodulation by…
Abstract Number: 0109 • ACR Convergence 2025
Application of Psoriatic Arthritis Mouse Models in Preclinical Pharmacodynamic Evaluation
Juan Liang¹ and Yinlian Zhang², ¹Gempharmatech, Nanjing, Jiangsu, China, ²GemPharmatech, Nanjing, China (People's Republic)
Background/Purpose: Psoriatic arthritis (PsA), a complex inflammatory disorder that affects up to 30% of psoriasis patients. It is marked by clinical heterogeneity and a lack…
Abstract Number: 0002 • ACR Convergence 2025
KITE-363: An Autologous Anti-CD19/CD20 CAR-T Product for the Treatment of Autoimmune Rheumatic Diseases
Brian Kim, Christine Lowe, Francisco Flores, Jeremy Margaitis, Alessandro Calo, Stacey Valny, Anna Konecny, Eva Jaghatspanyan, Sean Yoder, Kenneth Ertel, Simone Filosto, Jodi Murakami and David Barrett, Kite, a Gilead Company, Santa Monica, CA
Background/Purpose: B-cell dysregulation is a key factor in the development and progression of autoimmune diseases, and B-cell inhibition has been a cornerstone of treatment for…
Abstract Number: 0147 • ACR Convergence 2025
Rheumatoid Arthritis prevalence estimation in France using care pathways in the National Health Data System: opportunities and limitations – PREST study
cécile gaujoux-viala¹, adeline Ruyssen-Witrand², Laurent arnaud³, clélia Bignon-Favary⁴, Lauren Inchboard⁴ and Bruno Fautrel⁵, ¹Department of Rheumatology - CHU Nîmes, IDESP UM¹³¹⁸  INSERM – Univ. Montpellier, Nîmes, France, Nîmes, France, ²Department of Rheumatology, C.H.U. de Toulouse, CIC ¹⁴³⁶, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France, Toulouse, France, ³Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, INSERM UMR-S ¹¹⁰⁹, Strasbourg, France, Strasbourg, France, ⁴Horiana, Statistiques, Bordeaux, France, Bordeaux, France, ⁵Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: A total of 98.8% of French citizens are registered in the National Health Data System (SNDS), which includes claims data of all reimbursed health-related…
Abstract Number: 0129 • ACR Convergence 2025
Analysis of Antiphosphatidylserine/prothrombin Antibodies as a Predictor of Lupus Anticoagulant in the Pediatric Population
Jonathan Marilao¹, Sean Yates² and Elizabeth Sloan³, ¹University of Texas Southwestern, Dallas, TX, ²University of Texas Southwestern, Dallas, ³UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX
Background/Purpose: Antiphospholipid Syndrome (APS) is a systemic thromboinflammatory autoimmune disease characterized by thrombotic or obstetric events occurring in individuals with persistently positive antiphospholipid antibodies (aPL).…
Abstract Number: 0148 • ACR Convergence 2025
Air Pollution as a Trigger for Flares in Chronic Inflammatory Rheumatic Diseases: a Prospective Single-Center Study in the South of France
Coralie Cruzel¹, antonio Iannelli², Alexandre Armengaud³, Sonia Oppo³, Marie Charlotte Trojani⁴, Stephanie Ferrero⁴, Veronique Breuil⁴, Eric Fontas⁵, Christian Roux⁴ and Clément Viala⁴, ¹². Department of Clinical Research, Cimiez Hospital, CHU Nice, Université Côte d'Azur, Nice, France, France, France, ²³. Centre Hospitalier Universitaire de Nice-Digestive Surgery and Liver Transplantation Unit, Archet ² Hospital, ⁰⁶²⁰² Nice, France., NIce, France, ³¹. University Cote d’Azur, Rheumatology department, CHU Nice, France, Marseille, France, ⁴¹. University Cote d’Azur, Rheumatology department, CHU Nice, France, NIce, France, ⁵². Department of Clinical Research, Cimiez Hospital, CHU Nice, Université Côte d'Azur, Nice, France, NIce, France
Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA), are chronic inflammatory rheumatic diseases. Despite significant advancements in their management through novel therapies, some patients continue to…
Abstract Number: 0091 • ACR Convergence 2025
Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Rheumatoid Arthritis: associations with treatment response and comorbidities
Athena Chin¹, susan branford², Annabelle Small³, malcolm Smith¹, monika Kutyna⁴, Robert King⁵, Susanna Proudman⁶, Devendra Hiwase⁷ and Mihir Wechalekar⁸, ¹Flinders Medical Centre, KURRALTA PARK, South Australia, Australia, ²SA Pathology, Adelaide, ³Flinders University, Bedford Park, South Australia, Australia, ⁴South Australian Health and Medical Research Institute, Adelaide, ⁵Flinders Medical Centre, Adelaide, South Australia, Australia, ⁶Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ⁷Royal Adelaide Hospital, Adelaide, ⁸Flinders Medical Centre and Flinders University, Bedford Park, South Australia, Australia
Background/Purpose: Clonal hematopoiesis (CH) of indeterminate potential (CHIP) is defined as the detection of recurrent somatic mutations, at a variant allele frequency (VAF) < ![if…
Abstract Number: 0162 • ACR Convergence 2025
Clinical Relevance of Systematic Comorbidity Screening in Autoimmune and Inflammatory Diseases
Martin Michaud, Caroline Arlet, Jean Alain Bournazeau, François de Maupeou, Julie Gaston, Stephanie Mermet, Helene Coulier, Marie Oustalet, Christophe Raspaud, Cédric Maurice, Sophie Recipon, Claire Verplancken, Kim Paricaud and Leonardo Astudillo, Clinique Saint Exupery, TOULOUSE, France
Background/Purpose: Chronic autoimmune and inflammatory diseases are associated with an increased prevalence of various comorbidities, which may impact both prognosis and therapeutic strategies. EULAR recommends…
Abstract Number: 0089 • ACR Convergence 2025
Expansion of PD-1hi Tfh and Tph cells in the peripheral blood of seropositive clinically suspect arthralgia patients: association with progression to rheumatoid arthritis
Maria-Eugenia Miranda-Carus¹, Mariana Gutierrez-Riart², Beatriz Nieto-Carvalhal³, Laura Nuño², Alejandro Villalba¹, Diana Peiteado¹, Irene Monjo Henry¹, Marta Novella-Navarro¹ and Eugenio de Miguel¹, ¹Hospital Universitario La Paz, Madrid, Spain, ²Hospital Universitario La Paz, Madrid, ³Hospital Universitario La Paz, Mdrid
Background/Purpose: Subjects with clinically suspect arthralgia (CSA) are at risk for developing rheumatoid arthritis (RA) and therapeutic interventions may prevent or delay progression. Still, a…
Abstract Number: 0135 • ACR Convergence 2025
Rituximab in Antiphospholipid Syndrome: aPL Titer Decline and Clinical Outcomes
Omer Uludag¹, Soner Altın², Gamze Kemec², yasemin yalcinkaya³, Ahmet Gul³, Murat Inanc³ and Bahar Artim Esen⁴, ¹Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey, ³Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, ⁴Istanbul University, Istanbul, Istanbul, Turkey
Background/Purpose: Rituximab treatment has been shown to be effective in non-thrombotic manifestations of APS and refractory catastrophic APS (CAPS). However, there are conflicting results regarding…
Abstract Number: 0180 • ACR Convergence 2025
Digital Transformation in IMID Care: Results from the Implementation of IMIDOC
JOSE INIESTA-CHAMORRO¹, Marta Novella-Navarro², Diego Benavent³, HELENA BORREL-PAÑOS⁴, Xabier Michelena Vegas⁵, Javier Bachiller⁶, Verónica García García⁷, ESTHER ESPARTAL⁴, LETICIA LOJO-OLIVEIRA⁸, Enrique Calvo-Aranda⁹, José Rodríguez gago¹⁰, Gema Bonilla¹¹, Irene Monjo Henry², Victoria Navarro-Compan¹², Jaime Arroyo¹⁰, Eugenio de Miguel², Mariana Díaz-Almirón¹³, cARMEN ALEGRE¹⁰, ENRIQUE J GÓMEZ¹⁴ and Chamaida Plasencia-Rodríguez², ¹¹Biomedical Engineering and Telemedicine Centre, ETSIT, Center for Biomedical Technology, Universidad Politéctica de Madrid, TELEMEDICINE, MADRID, ²Hospital Universitario La Paz, Madrid, Spain, ³Hospital Universitari de Bellvitge, Madrid, Spain, ⁴⁴HOSPITAL UNIVERSITARIO VALL D´HEBRON, RHEUMATOLOGY, BARCELONA, Spain,, BARCELONA, ⁵Hospital Universitari Vall Hebron, Barcelona, Spain, ⁶Hospital Ramon y Cajal, Madrid, Madrid, Spain, ⁷Ramón y Cajal University Hospital, MADRID, Spain, ⁸Hospital Universitario Infanta Leonor, Madrid, Spain, ⁹Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, madrid, ¹⁰Hospital Universitario La Paz, MADRID, ¹¹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ¹²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ¹³LIMA, Advanced Medical Informatics Lab, La Paz Research Institute, IdiPAZ, Madrid, Spain, ¹⁴¹Biomedical Engineering and Telemedicine Centre, ETSIT, Center for Biomedical Technology, Universidad Politéctica de Madrid, TELEMEDICINE, MADRID, Spain,, MADRID
Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA) are immune-mediated inflammatory diseases (IMIDs) characterized by joint and spinal inflammation, leading to functional impairment. Their management requires…
Abstract Number: 0167 • ACR Convergence 2025
Geographic and Demographic Patterns of Rheumatoid Arthritis in the United States: Insights from GBD 2021
Punith Chirumamilla¹, Sameer Kumar Majety², Rithish Nimmagadda³, Ravi Medarametla⁴, Priya Sunkara⁵, Pranathi Bandarupalli⁶, Anjani Mahesh Kumar Cherukuri⁷ and Himaja Anne⁸, ¹Baptist Memorial Hospital North Mississippi, Oxford, MS, ²School of Medicine, Xiamen University, China, Kakinada, Andhra Pradesh, India, ³One Brooklyn Health, New York, NY, ⁴Mamata Medical College, Guntur, Andhra Pradesh, India, ⁵White River Health, Batesville, AZ, ⁶Mercy St Vincent Medical Center, Toledo, OH, ⁷Guntur Medical College, Guntur, Andhra Pradesh, India, ⁸Hind Institute of Medical Sciences, Sitapur, Uttar Pradesh, India
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune, systemic disease with a rising U.S. healthcare burden. Utilizing Global Burden of Disease (GBD) 2021 estimates, we analyzed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].